Acute-phase Disease and Super-responder Status Predict Reduced Relapse Risk After Ritlecitinib Withdrawal in Alopecia Areata: A Prospective Real-World Study
Published: 22 June 2026| Version 1 | DOI: 10.17632/ykwsrp4ymh.1
Contributor:
敏 李Description
Acute-phase disease and super-responder status independently predict lower relapse risk following ritlecitinib discontinuation, supporting early intervention and risk-stratified management in alopecia areata.
Files
Categories
Health Sciences